GlassScriptPhysician profile
David W Koh
NPI 1154361038
$14,312.68
in general payments reported to CMS, 2019-2025
34 companies · $8,616 in 2025
The $8,616 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $43.02 · 2021: $448 · 2022: $855 · 2023: $2,872 · 2024: $1,135 · 2025: $8,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $4,745 · Travel and Lodging: $2,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $4,745.03 |
| Travel and Lodging | $2,377.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,649.42 | 2025 | |
| Inspire Medical Systems, INC. | $2,525.97 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,515.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $752.73 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.08 | 2021-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $351.24 | 2021-2025 | Trelegy Ellipta, Nucala |
| Avadel Cns Pharmaceuticals, LLC | $185.71 | 2023-2025 | Lumryz |
| Genzyme Corporation | $178.68 | 2023-2025 | |
| Amgen INC. | $159.88 | 2022-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $125.89 | 2019-2024 | |
| Insmed, INC. | $113.46 | 2024-2025 | Arikayce |
| Viatris Specialty LLC | $105.97 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $104.81 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $90.90 | 2019 | |
| Electromed, INC. | $86.09 | 2023-2025 | Smartvest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $81.76 | 2024-2025 | Glassia, Hyqvia |
| Verona Pharma, INC. | $73.60 | 2025 | Ohtuvayre |
| Itamar Medical INC | $72.04 | 2023 | Watchpatone |
| Vapotherm INC | $65.23 | 2021-2022 | |
| Boston Scientific Corporation | $59.07 | 2022 | |
| Harmony Biosciences LLC | $56.21 | 2025 | |
| Mylan Specialty L.P. | $51.66 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $43.27 | 2025 | Prolastin-C Liquid |
| Natus Medical Incorporated | $41.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.24 | 2023 | Eliquis |
| Lilly USA, LLC | $27.23 | 2025 | Zepbound |
| Healthmyne, INC. | $21.00 | 2019 | |
| Resmed Corp | $20.46 | 2025 | |
| Siemens Medical Solutions USA, INC. | $18.54 | 2023 | Rapidpoint 400/405/500 Wash/Waste Cartridge |
| Fisher & Paykel Healthcare INC | $18.18 | 2024 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $15.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.39 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David W Koh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.